Primary Endpoints In Phase III Plaque Psoriasis Trial
21/09/2026 02:25
BRIEF-Hansoh Pharmaceutical Says HS-10374 Meets Co-Primary Endpoints In Phase III Plaque Psoriasis Trial Sept 21 (Reuters) - Hansoh Pharmaceutical Group Company Limited 3692.HK:
HS-10374 MEETS CO-PRIMARY ENDPOINTS IN PHASE III PLAQUE PSORIASIS TRIAL
Further company coverage: 3692.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansoh Pharmaceutical
See all newsHansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion